Skip to main content
SpringerLink
Log in

The Use of Ozone as Redox Modulator in the Treatment of the Chronic Obstructive Pulmonary Disease (COPD)

  • Chapter
  • First Online:
Oxidative Stress in Lung Diseases

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex and progressive disease associated with an overproduction of reactive oxygen species (ROS), circulating pro-inflammatory cytokines, and acute-phase proteins. This generalized oxidative/inflammatory status is accompanied by a downregulation of the cellular antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2).Therapeutic agents that activate Nrf2 may have a pivotal role in the rebalance of the altered redox system. This chapter explores how the ozone can act as an endogenous redox modulator in the integrated treatment of COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reinhard CT, Planavsky NJ, Olson SL et al (2016) Earth’s oxygen cycle and the evolution of animal life. Proc Natl Acad Sci U S A 113:8933–8938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Taverne YJ, Merkus D, Bogers AJ et al (2018) Reactive oxygen species: radical factors in the evolution of animal life. Bioessays 40. https://doi.org/10.1002/bies.201700158

    Article  CAS  Google Scholar 

  3. Halliwell B, Gutteridge JMC (2015) Free radicals in biology and medicine, 5th edn. Clarendon Press, Oxford

    Book  Google Scholar 

  4. Halliwell B (1996) Free radicals, proteins and DNA: oxidative damage versus redox regulation. Biochem Soc Trans 24:1023–1027

    Article  CAS  PubMed  Google Scholar 

  5. Holguin F (2013) Oxidative stress in airway diseases. Ann Am Thorac Soc 10:S150–S157

    Article  PubMed  CAS  Google Scholar 

  6. van der Vliet A, O’Neill CA, Cross CE et al (1999) Determination of low – molecular mass antioxidant concentrations in human respiratory tract lining fluids. Am J Physiol 276:L289–L296

    PubMed  Google Scholar 

  7. Kinnula VL, Crapo JD (2003) Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 167:1600–1619

    Article  PubMed  Google Scholar 

  8. Kollek I, Sinha P, Rustow B (2002) Vitamin E as an antioxidant of the lung: mechanisms of vitamin E delivery to alveolar type II cells. Am J Respir Crit Care Med 166:S62–S66

    Article  Google Scholar 

  9. Rahman I, Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Rep J 28:219–242

    Article  CAS  Google Scholar 

  10. Kinnula VL, Fattman CL, Tan RJ et al (2005) Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 172:417–422

    Article  PubMed  PubMed Central  Google Scholar 

  11. Esme H, Cemek M, Sezer M et al (2008) High levels of oxidative stress in patients with advanced lung cancer. Respirology 13:112–116

    Article  PubMed  Google Scholar 

  12. Kirkham PA, Barnes PJ (2013) Oxidative stress in COPD. Chest 1:266–273

    Article  CAS  Google Scholar 

  13. Fischer BM, Pavlisko E, Voynow JA (2011) Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance and inflammation. Int J Chron Obstruct Pulmon Dis 6:413–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. van Eeden SF, Sin DD (2008) Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 75:224–238

    Article  PubMed  Google Scholar 

  15. Kido T, Tamagawa E, Bai N (2011) Particulate matter induces translocation of IL-6 from the lung to systemic circulation. Am J Respir Cell Mol Biol 44:197–204

    Article  CAS  PubMed  Google Scholar 

  16. Iizuka T, Ishii Y, Itoh K et al (2005) Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 10:1113–1125

    Article  CAS  PubMed  Google Scholar 

  17. Cho HY, Kleeberger SR (2010) Nrf2 protects against airway disorders. Toxicol Appl Pharmacol 244:43–56

    Article  CAS  PubMed  Google Scholar 

  18. Itoh K, Chiba T, Takahashi S et al (1997) An Nrf2/smal Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313–322

    Article  CAS  PubMed  Google Scholar 

  19. Malhotra D, Thimmulappa R, Navas-Ancien A et al (2008) Decline in Nrf2-regualted antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, dj-1. Am J Respir Crit Care Med 178:592–604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Goven D, Boutten A, Lecon-Malas V et al (2008) Altered Nrf2/Keap 1-Bach1 equilibrium in pulmonary emphysema. Thorax 63:916–924

    Article  CAS  PubMed  Google Scholar 

  21. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARA pathway. Annu Rev Pharmacol Toxicol 47:89–116

    Article  CAS  PubMed  Google Scholar 

  22. Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-fos and fra1 negatively regulate the human antioxidant response element -mediated expression of NAD(P): Quinone oxidoreductase 1 gene. Proc Natl Acad Sci U S A 93:14960–14965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Suzuki M, Betsuyaku T, Ito Y et al (2008) Down-regulated Nf-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 39:673–682

    Article  CAS  PubMed  Google Scholar 

  24. Rahman I, MacNee W (2012) Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Biswas A, Hwang JW, Kirkham PA et al (2013) Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem 20:1496–1530

    Article  CAS  PubMed  Google Scholar 

  26. Biswal S, Timmulappa RK, Harvey CJ (2012) Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD. Proc Am Thorac Soc 9:47–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Suzuki M, Betsuyaku T, Ito Y et al (2009) Curcumin attenuates elastase-and cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol 296:L614–L623

    Article  CAS  PubMed  Google Scholar 

  28. Tabak C, Arts IC, Smit HA et al (2001) Chronic obstructive pulmonary disease and intake of catechins, flavonols and flavones: the Morgen study. Am J Respir Crit Care Med 164:61–64

    Article  CAS  PubMed  Google Scholar 

  29. Schols AM (2013) Nutrition as a metabolic modulator in COPD. Chest 144:1340–1345

    Article  CAS  PubMed  Google Scholar 

  30. Dianzani MU (2003) 4-Hydroxynonenal from pathology to physiology. Mol Aspects Med 24:263–272

    Article  PubMed  CAS  Google Scholar 

  31. Forman HJ, Maiorino M, Ursini F (2010) Signaling functions of reactive oxygen species. Biochemistry 49:835–842

    Article  CAS  PubMed  Google Scholar 

  32. Brigelius-Flohè R, Flohè L (2011) Basic principles and emerging concepts in the redox control of transcription factors. Antioxidants and Redox Signaling 15:2335–2381

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. Taguchi K, Yamamoto M (2011) Molecular mechanisms of Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16:123–140

    Article  CAS  PubMed  Google Scholar 

  34. Menegon S, Columbano A, Giordano S (2016) The dual roles of Nrf2 in cancer. Trends Mol Med 22:578–593

    Article  CAS  PubMed  Google Scholar 

  35. Bocci V (1998) Is ozone therapy therapeutic ? Perspect Biol Med 42:131–143

    Article  CAS  PubMed  Google Scholar 

  36. Bocci V, Aldinucci C, Borrelli E et al (2001) Ozone in medicine. Ozone Sci Eng 23:207–217

    Article  CAS  Google Scholar 

  37. Bocci V (2006) Scientific and medical aspects of ozone therapy. State of art. Arch Med Res 37:425–435

    Article  CAS  PubMed  Google Scholar 

  38. Borrelli E, Diadori A, Zalaffi A (2012) Effect of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study. Int J Ophthalmol 5:708–713

    PubMed  PubMed Central  Google Scholar 

  39. Borrelli E, Bocci V (2014) Oxygen ozone therapy in the treatment of chronic obstructive pulmonary disease: an integrative approach. Am J Clin Exp Med 2:9–13

    Article  CAS  Google Scholar 

  40. Borrelli E, De Monte A, Bocci V (2015) Oxygen ozone therapy in the integrated therapy of chronic ulcer: a case series report. Int J Rec Sci Res 5:4132–4136

    Google Scholar 

  41. Giunta R, Coppola A, Luongo C et al (2001) Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol 80:745–748

    Article  CAS  PubMed  Google Scholar 

  42. Bocci V (2005) Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 208:117–126

    Article  CAS  Google Scholar 

  43. Bocci V, Valacchi G, Corradeschi F et al (1998) Studies on biological effects of ozone 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents 12:67–75

    CAS  PubMed  Google Scholar 

  44. Bocci V, Borrelli E, Travagli V et al (2009) The ozone paradox. Ozone is a strong oxidant as well as a medical drug. Med Res Rev 29:646–682

    Article  CAS  PubMed  Google Scholar 

  45. Borrelli E, Bocci V (2010) Basic biological and therapeutic effects of ozone therapy in medicine. In: Ozone science and technology. Encyclopedia of Life Support Systems (EOLSS), developed under the auspices of the UNESCO. EOLSS Publishers, Oxford

    Google Scholar 

  46. Sirinki N, Suzuki T, Takama K et al (1998) Susceptibilities of plasma antioxidants and erythrocytes constituents to low levels of ozone. Hematologia 29:229–239

    Google Scholar 

  47. Bocci V, Borrelli E (2015) A practical approach for restoring homeostasis in diseases characterized by a chronic oxidative stress. J Adv Med Pharm Sci 2:135–143

    Google Scholar 

  48. Bocci V (2011) Ozone: a new medical drug, 2nd edn. Springer, Dordrecht

    Book  Google Scholar 

  49. Smith NL, Wilson AL, Gandhi J et al (2017) Ozone therapy: an overview of pharmacodynamics, current research and clinical utility. Med Gas Rev 7:212–219

    Article  CAS  Google Scholar 

  50. Akbudak IH, Kucukatay V, Kilic-Erkek O et al (2018) Investigation of the effects of major ozone autohemotherapy application on erythrocyte deformability and aggregation. Clin Hemorheol Microcirc. https://doi.org/10.3233/CH-180417

    Article  CAS  PubMed  Google Scholar 

  51. Pecorelli A, Bocci V, Acquaviva A et al (2013) Nrf2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol 267:30–40

    Article  CAS  PubMed  Google Scholar 

  52. Bocci V, Aldinucci C (2006) Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol 20:133–138

    Article  CAS  PubMed  Google Scholar 

  53. Pinto-Plata VM, Cote C, Cabral H et al (2004) The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23:28–33

    Article  CAS  PubMed  Google Scholar 

  54. Holland AE, Hill CJ, Rasekaba A et al (2010) Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arc Phys Med Rehabil 91:221–225

    Article  Google Scholar 

  55. Jones PW (2005) St. George’s respiratory questionnaire: MCID. COPD-J Chron Obstruct Pulmon Dis 2:111–124

    Article  Google Scholar 

  56. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2017). Available from: https://goldcopd.org

  57. Lee IT, Yang CM (2013) Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013:791231

    PubMed  PubMed Central  Google Scholar 

  58. Koskela J, Kilpelainen M, Kupiainen H et al (2014) Co -morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med 14:102

    Article  PubMed  PubMed Central  Google Scholar 

  59. Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provide an interface between redox and intermediary metabolism. Trends Biochem Sci 214:199–218

    Article  CAS  Google Scholar 

  60. Bocci V, Borrelli E (2015) It is time that Health Authorities promote the use of oxygen ozone therapy as an integrative therapy of orthodox drugs. Br J Med Med Res 10:1–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biotechnologies, University of Siena, Siena, Italy

    Emma Borrelli

Authors
  1. Emma Borrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma Borrelli .

Editor information

Editors and Affiliations

  1. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Sajal Chakraborti

  2. Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

    Narasimham L. Parinandi

  3. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Rita Ghosh

  4. Apollo Hospitals Educational & Research Foundation (AHERF), Indraprastha Apollo Hospitals, New Delhi, Delhi, India

    Nirmal K. Ganguly

  5. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Tapati Chakraborti

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Borrelli, E. (2020). The Use of Ozone as Redox Modulator in the Treatment of the Chronic Obstructive Pulmonary Disease (COPD). In: Chakraborti, S., Parinandi, N., Ghosh, R., Ganguly, N., Chakraborti, T. (eds) Oxidative Stress in Lung Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-32-9366-3_18

Download citation

Publish with us

Policies and ethics

Search

Navigation